Press release
Advanced Renal Cell Carcinoma Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharma, Chia Tai T
"Advanced Renal Cell Carcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma Market.
The Advanced Renal Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Advanced Renal Cell Carcinoma Pipeline Report: https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Advanced Renal Cell Carcinoma treatment therapies with a considerable amount of success over the years.
• Advanced Renal Cell Carcinoma companies working in the treatment market are Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others, are developing therapies for the Advanced Renal Cell Carcinoma treatment
• Emerging Advanced Renal Cell Carcinoma therapies in the different phases of clinical trials are- OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others are expected to have a significant impact on the Advanced Renal Cell Carcinoma market in the coming years.
• In December 2024, At the 2024 Society of Urologic Oncology (SUO) annual meeting in Dallas, Belzutifan was highlighted for its approval in multiple countries, including the United States and Canada, for treating patients with VHL disease-associated neoplasms. In the U.S., it is also approved for adult patients with advanced renal cell carcinoma (RCC) who have previously undergone treatment with a PD-(L)1 inhibitor and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI). Several studies have investigated the use of Belzutifan in advanced RCC patients. Dr. Jonasch presented the findings of a post hoc pooled analysis of Belzutifan's safety in RCC patients who received a 120 mg daily dose across the LITESPARK-001, LITESPARK-004, LITESPARK-005, and LITESPARK-013 studies.
• In November 2024, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology firm focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, has announced the initiation of patient enrollment for its Phase 1 clinical trial assessing ADI-270 in individuals with metastatic or advanced clear cell renal cell carcinoma (ccRCC).
• In September 2024, NiKang Therapeutics® Inc., a clinical-stage biotech company dedicated to developing innovative small molecule oncology treatments, announced that preliminary results from its ongoing Phase 1/2 clinical trial of NKT2152 for advanced clear cell renal cell carcinoma (ccRCC) in patients who have previously received treatment will be shared through an oral presentation at the European Society for Medical Oncology (ESMO) 2024 Congress.
Advanced Renal Cell Carcinoma Overview
Advanced Renal Cell Carcinoma (RCC) refers to a stage of kidney cancer where the cancer has spread beyond the kidney to other parts of the body. Renal cell carcinoma originates in the lining of small tubes in the kidney and can progress to an advanced stage if it metastasizes or spreads to nearby lymph nodes or distant organs.
Get a Free Sample PDF Report to know more about Advanced Renal Cell Carcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Advanced Renal Cell Carcinoma Drugs Under Different Phases of Clinical Development Include:
• OATD-02: Molecure S.A.
• DS-6000a: Daiichi Sankyo
• JANX008: Janux Therapeutics
• NKT2152: NiKang Therapeutics
• CMN-001: CoImmune
• IPI-549: Infinity Pharmaceuticals
• TQB2450: Chia Tai TianqingPharmaceutical
• Belzutifan: Merck Sharp & Dohme
• Atezolizumab: Hoffmann-La Roche
• Volrustomig: AstraZeneca
• XmAb819: Xencor
Advanced Renal Cell Carcinoma Route of Administration
Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Advanced Renal Cell Carcinoma Molecule Type
Advanced Renal Cell Carcinoma Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment
• Advanced Renal Cell Carcinoma Assessment by Product Type
• Advanced Renal Cell Carcinoma By Stage and Product Type
• Advanced Renal Cell Carcinoma Assessment by Route of Administration
• Advanced Renal Cell Carcinoma By Stage and Route of Administration
• Advanced Renal Cell Carcinoma Assessment by Molecule Type
• Advanced Renal Cell Carcinoma by Stage and Molecule Type
DelveInsight's Advanced Renal Cell Carcinoma Report covers around 60+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Advanced Renal Cell Carcinoma product details are provided in the report. Download the Advanced Renal Cell Carcinoma pipeline report to learn more about the emerging Advanced Renal Cell Carcinoma therapies
https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Advanced Renal Cell Carcinoma Therapeutics Market include:
Key companies developing therapies for Advanced Renal Cell Carcinoma are - erck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, Teon Therapeutics, Asher Biotherapeutics, Shanghai Junshi Biosciences, Surface Oncology, ProfoundBio, Portage Biotech, Novartis Pharmaceuticals, HiFiBiO, and others.
Advanced Renal Cell Carcinoma Pipeline Analysis:
The Advanced Renal Cell Carcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Renal Cell Carcinoma Treatment.
• Advanced Renal Cell Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Renal Cell Carcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Advanced Renal Cell Carcinoma drugs and therapies
https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Advanced Renal Cell Carcinoma Pipeline Market Drivers
• Increasing Prevalence in Advanced Renal Cell Carcinoma, increase in the number of research and development activities are some of the important factors that are fueling the Advanced Renal Cell Carcinoma Market.
Advanced Renal Cell Carcinoma Pipeline Market Barriers
• However, side-effects associated with the treatment of Advanced Renal Cell Carcinoma, cost associated with the treatment and other factors are creating obstacles in the Advanced Renal Cell Carcinoma Market growth.
Scope of Advanced Renal Cell Carcinoma Pipeline Drug Insight
• Coverage: Global
• Key Advanced Renal Cell Carcinoma Companies: Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others
• Key Advanced Renal Cell Carcinoma Therapies: OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others
• Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
• Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers
Request for Sample PDF Report for Advanced Renal Cell Carcinoma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Advanced Renal Cell Carcinoma Report Introduction
2. Advanced Renal Cell Carcinoma Executive Summary
3. Advanced Renal Cell Carcinoma Overview
4. Advanced Renal Cell Carcinoma- Analytical Perspective In-depth Commercial Assessment
5. Advanced Renal Cell Carcinoma Pipeline Therapeutics
6. Advanced Renal Cell Carcinoma Late Stage Products (Phase II/III)
7. Advanced Renal Cell Carcinoma Mid Stage Products (Phase II)
8. Advanced Renal Cell Carcinoma Early Stage Products (Phase I)
9. Advanced Renal Cell Carcinoma Preclinical Stage Products
10. Advanced Renal Cell Carcinoma Therapeutics Assessment
11. Advanced Renal Cell Carcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Renal Cell Carcinoma Key Companies
14. Advanced Renal Cell Carcinoma Key Products
15. Advanced Renal Cell Carcinoma Unmet Needs
16 . Advanced Renal Cell Carcinoma Market Drivers and Barriers
17. Advanced Renal Cell Carcinoma Future Perspectives and Conclusion
18. Advanced Renal Cell Carcinoma Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports:
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Renal Cell Carcinoma Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharma, Chia Tai T here
News-ID: 3835253 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
